The NCR does not capture some clinicopathologic information specific to GIST, including tumor–node–metastasis stage, risk classification of resected GIST, genetic mutations of KIT and PDGFRA, specific drug names and doses of chemotherapy, and the efficacy and safety of each treatment. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.